SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Faruqi & Faruqi, LLP, a national securities‑law firm, has announced it is investigating possible claims against Jasper Therapeutics, Inc. (NASDAQ: JSPR) on behalf of investors who purchased or acquired Jasper securities between November 30, 2023 and July 3, 2025. The firm says the deadline to seek lead‑plaintiff status in the federal securities class action is November 18, 2025. The complaint alleges that Jasper and its executives made false and/or misleading public statements (or omitted material facts) by failing to disclose: (i) that Jasper lacked appropriate controls and procedures to ensure that third‑party manufacturers complied with current Good Manufacturing Practice (cGMP) regulations in producing drug‑product lots; (ii) that this deficiency increased the risk of confounded clinical‑trial results, impairing the regulatory and commercial prospects of the company’s drug candidate (briquilimab); (iii) that accordingly, Jasper’s business outlook and clinical/commercial prospects were overstated. In its July 7, 2025 press release, Jasper disclosed that a specific drug‑product lot used in its BEACON and ETESIAN studies appeared to have manufacturing issues: 10 of 13 patients in certain cohorts received that lot, the company paused study dosing, halted SCID development and announced cost‑cutting and restructuring measures to extend its cash runway beyond its previously claimed third‑quarter 2025 liquidity. Upon that news, the company’s stock plunged approximately 55%. Faruqi & Faruqi invites affected shareholders, former employees, whistle‑blowers or individuals with information regarding the company’s conduct to contact the firm. Your decision whether to serve as lead plaintiff does not affect your right to share in any recovery. #JasperTherapeutics #SecuritiesClassAction #InvestorRights #FaruqiLaw #SlimScan #GrowthStocks #CANSLIM